IVVD Logo

Invivyd, Inc. (IVVD) 

NASDAQ$0.7642-0.04 (-4.97%)
Market Cap
$96.25M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
660 of 924
Rank in Industry
374 of 527

IVVD Insider Trading Activity

IVVD Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$1,023,52916100

Related Transactions

MCGUIRE TERRANCEdirector0$016$1.02M$-1.02M

About Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research …

Insider Activity of Invivyd, Inc.

Over the last 12 months, insiders at Invivyd, Inc. have bought $0 and sold $1.02M worth of Invivyd, Inc. stock.

On average, over the past 5 years, insiders at Invivyd, Inc. have bought $0 and sold $10.39M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Invivyd, Inc.

2024-12-31SaleMCGUIRE TERRANCEdirector
103,474
0.0894%
$0.45$46,098+106.48%
2024-12-30SaleMCGUIRE TERRANCEdirector
86,545
0.0685%
$0.48$41,784+90.73%
2024-12-27SaleMCGUIRE TERRANCEdirector
83,744
0.0705%
$0.52$43,647+65.86%
2024-12-26SaleMCGUIRE TERRANCEdirector
83,817
0.0712%
$0.54$45,563+59.16%
2024-12-24SaleMCGUIRE TERRANCEdirector
68,161
0.0566%
$0.51$34,503+65.23%
2024-12-23SaleMCGUIRE TERRANCEdirector
75,776
0.0605%
$0.45$34,076+75.60%
2024-12-20SaleMCGUIRE TERRANCEdirector
119,805
0.1005%
$0.42$50,725+82.92%
2024-12-19SaleMCGUIRE TERRANCEdirector
152,067
0.1277%
$0.43$65,951+88.12%
2024-12-18SaleMCGUIRE TERRANCEdirector
74,764
0.066%
$0.47$35,087+80.99%
2024-12-17SaleMCGUIRE TERRANCEdirector
97,410
0.0782%
$0.48$46,757+38.95%
2024-12-16SaleMCGUIRE TERRANCEdirector
65,359
0.0553%
$0.47$30,510+23.64%
2024-12-12SaleMCGUIRE TERRANCEdirector
125,000
0.1041%
$0.58$72,875-5.67%
2024-12-11SaleMCGUIRE TERRANCEdirector
160,400
0.135%
$0.59$94,812-5.48%
2024-12-10SaleMCGUIRE TERRANCEdirector
175,000
0.1459%
$0.59$103,005-7.17%
2024-12-09SaleMCGUIRE TERRANCEdirector
150,000
0.1261%
$0.61$91,560-3.65%
2024-05-29SaleMCGUIRE TERRANCEdirector
112,381
0.2233%
$1.66$186,575-41.00%
2024-01-19SaleAdimab, LLC10 percent owner
5M
23.6347%
$3.95$19.75M-74.47%
Total: 17
*Gray background shows transactions not older than one year

IVVD Institutional Investors: Active Positions

Increased Positions36+42.35%14M+19.15%
Decreased Positions32-37.65%8M-11.87%
New Positions13New12MNew
Sold Out Positions13Sold Out5MSold Out
Total Postitions89+4.71%77M+7.27%

IVVD Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Maverick Capital Ltd$9,471.009.81%11.77M00%2024-12-31
Mithril Ii Gp Lp$9,049.009.37%11.24M+11MNew2024-12-31
Deep Track Capital, Lp$8,605.008.91%10.69M-264,334-2.41%2024-12-31
M28 Capital Management Lp$7,445.007.71%9.25M00%2024-12-31
Fmr Llc$4,649.004.81%5.78M-2M-21.11%2024-12-31
Blackrock, Inc.$3,819.003.95%4.74M+71,833+1.54%2024-12-31
Vanguard Group Inc$3,494.003.62%4.34M-25,906-0.59%2024-12-31
Redmile Group, Llc$2,425.002.51%3.01M-53,460-1.74%2024-12-31
683 Capital Management, Llc$2,415.002.5%3M00%2024-12-31
Bain Capital Life Sciences Investors, Llc$1,449.001.5%1.8M00%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.